Activity Assay Kits

Z-Glutamyl(γ-hydroxamate)-glycine



Order
Quantity
Price
Status
100 mg 125 € available


Documents
Art. No. Z018
Synonym Z-Glu(γ-hydroxamate)-Gly-OH
Background info The standard hydroxamate assay uses Z-Gln-Gly-OH as peptidic glutamine substrate and hydroxylamine as amine donor. In the presence of MTG, hydroxylamine is enzymatically incorporated into the peptide to form Z-Glutamyl(γ-hydroxamate)-glycine. The hydroxamate forms a red colored complex with iron (III) ions quantified at 525 nm.
One unit of microbial transglutaminase activity is defined as the amount of enzyme, which causes the formation of 1.0 μmole of hydroxamate per minute at 37ºC (Folk and Cole, 1966).
Z018 represents the reaction product to be measured by the chromogenic endpoint assay, allowing the determination of a calibration curve. For each setting, molar attenuation coefficient (ε) needs to be determined individually.
We recommend using Z018 to replace G048, which represents the glutamyl(γ-hydroxamate) as a surrogate only.
Molecular Formula C15H19N3O7
Molecular Weight 353.33
Appearance White solid
Solubility >50 mM in aqueous buffers
Dissolve e.g. 10 mg (28.3 μmol) of Z018 in 566 μL of aqueous buffer to obtain a 50 mM (17.7 mg/mL) stock solution.
Application Reference substance to determine the concentration of product formed by microbial transglutaminase (MTG).
Storage Store at -20°C, desiccate
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy